[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100176795":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":19,"centralContacts":18,"locations":24,"responsibleParty":37,"collaborators":18,"id":41,"slug":42,"hasResults":43,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":43,"sex":48,"minAge":49,"maxAge":18,"enrollmentInfo":50,"targetDuration":18,"studyType":53,"phases":54,"briefSummary":56,"conditions":57,"keywords":18,"overallStatus":59,"whyStopped":18,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":69},{"fullName":5,"class":6},"Fundacion Clinic per a la Recerca Biomédica","OTHER",[8],{"label":9,"type":6,"description":10,"interventionNames":11},"GADOXETIC ACID","Is a non comparative study. a magnetic resonance will be done using gadoxetic acid : 0.025mmol\u002FKg",[12],"Drug: GADOXETIC ACID",[14],{"type":15,"name":9,"description":16,"armGroupLabels":17,"otherNames":18},"DRUG","all patients will have a magnetic resonance with gadobutrol as reference for diagnosis; in participants an additional magnetic resonance will be done with the new contrast agent to verify if the diagnostic can be done.",[9],null,[20],{"name":21,"affiliation":22,"role":23},"Carmen Ayuso, Prof, PhD MD","Hospital Clínic of Barcelona","PRINCIPAL_INVESTIGATOR",[25],{"facility":26,"status":18,"city":27,"state":27,"zip":28,"country":29,"countryCode":30,"cosmosGeoPoint":31,"geoPoint":36,"contacts":18},"Hospital Clinic of Barcelona","Barcelona","08036","Spain","ES",{"type":32,"coordinates":33},"Point",[34,35],2.15899,41.38879,{"lat":35,"lon":34},{"type":38,"investigatorFullName":39,"investigatorTitle":40,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"SPONSOR_INVESTIGATOR","Sara Varea","Clinical Research Manager","100176795","phase-4-magnetic-resonance-with-gadoxetic-acid-for-the-diagnosis-of-hepatocellular-carcinoma-in-patients-with-liver-cirrhosis-evaluation-of-its-impact-for-the-non-invasive-diagnosis-100176795",false,"NCT01575574","Magnetic Resonance With Gadoxetic Acid for the Diagnosis of Hepatocellular Carcinoma in Patients With Liver Cirrhosis. Evaluation of Its Impact for the Non-invasive Diagnosis","PRIGA","Inclusion Criteria:\n\n* more than 18 years old\n* patient with diagnosis of liver cirrhosis Child Pugh A-B\n* Patients without previous hepatocellular carcinoma in whom ultrasound detects a suspicious hepatic lesion; solitary solid and well-defined nodule between 10 and 20mm\n* patients in whom diagnosis of hepatocellular carcinoma is a clinical need prior to treatment indication\n* patient that agree to participate signing informed consent form\n\nExclusion Criteria:\n\n* Patients with poor liver function who would have undergone transplantation even without hepatocellular carcinoma diagnosis (Child-Pugh C)\n* patients with previous diagnosis of hepatocellular carcinoma\n* patients with significant comorbidities that could prevent the optimum therapeutic decision in case of positive diagnosis of hepatocellular carcinoma\n* patients with severe clotting alterations that contraindicate the fine-needle biopsy -Patients with chronic kidney disease or glomerular filtration rate \\\u003C 30 ml\u002Fmin\n* patients with contraindications to perform magnetic resonance imaging (pacemaker, claustrophobia...)\n* Known hypersensitivity to study drugs or excipients\n* pregnancy or breastfeeding","ALL","18 Years",{"count":51,"type":52},74,"ACTUAL","INTERVENTIONAL",[55],"PHASE4","This is a study to evaluate the primovist as a new contrast agent useful to diagnostic of hepatocellular carcinoma",[58],"Hepatocellular Carcinoma","COMPLETED","2016-08-21",{"date":62,"type":63},"2016-08-23","ESTIMATED",{"date":65,"type":18},"2012-07",{"date":67,"type":52},"2016-07",{"name":39,"class":6},1]